

freedom.information@wvt.nhs.uk

12 September 2019

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST FOI2019/0144

Thank you for your request for information.

Wye Valley NHS Trust responds with the table below. Please be aware that many cancer related services are run on behalf of Wye Valley NHS Trust by Cheltenham Hospital under the auspices of Gloucestershire Hospitals NHS Foundation Trust, so some relevant statistics for patients of Wye Valley NHS Trust will be held there. Information on Gloucestershire Hospitals NHS FT FOI service can be found here: <https://www.gloshospitals.nhs.uk/about-us/our-trust/freedom-information/> . Please accept the Trust’s apologies for the delay in responding to your request. This was due to personnel changes which affected gathering the data for some of the questions. Thank you for your patience and understanding.

It is not possible to tell from the Trust’s PAS data how soon breast cancer was confirmed. The table below is a summary of the number of patients admitted to the Trust where the primary diagnosis was breast cancer but it needs to be made clear that this does not specifically answer the question above:

DiagnosisCode1	DiagnosisCodeDescription1	2013	2014	2015	2016	2017	2018	Grand Total
C500	Malignant neoplasm of nipple and areola	*	*	*	*	*	*	17
C501	Malignant neoplasm of central portion of breast	*	10	9	11	14	13	61

C502	Malignant neoplasm of upper-inner quadrant of breast	13	*	14	8	6	17	62
C503	Malignant neoplasm of lower-inner quadrant of breast	*	8		*	9	*	30
C504	Malignant neoplasm of upper-outer quadrant of breast	31	28	21	34	34	46	194
C505	Malignant neoplasm of lower-outer quadrant of breast	14	10	8	*	*	7	47
C506	Malignant neoplasm of axillary tail of breast		*	1	*	*	*	*
C508	Malignant neoplasm, overlapping lesion of breast	*	*	*	*	*	*	17
C509	Malignant neoplasm of breast, unspecified	107	100	117	92	88	92	596
D050	Lobular carcinoma in situ	*		*				*
D051	Intraductal carcinoma in situ	7	11	24	12	12	12	78
D059	Carcinoma in situ of breast, unspecified	11	12	*	*	6	*	38

* This relates to a low number. Under section 40(ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trust's obligations to protect personal data under the Data Protection Act 2018 and General Data Protection Regulation 2018.

Request 1

Please confirm or deny if Wye Valley NHS Trust holds information on the number of people diagnosed in Wye Valley NHS Trust with early breast cancer in each year from 2013 to 2018.

If confirm, please release this data.

Request 2

Please confirm or deny if Wye Valley NHS Trust holds information on the number of people diagnosed in Wye Valley NHS Trust with early breast cancer that were offered tumour profiling tests to guide adjuvant chemotherapy decisions, in each year from 2013 to 2018.

If confirm, please release this data.

Request 3

Please confirm or deny if Wye Valley NHS Trust holds information on the number of people diagnosed in Wye Valley NHS Trust with early breast cancer that were tested with tumour profiling tests to guide adjuvant chemotherapy decisions, in each year from 2013 to 2018.

If confirm, please release this data.

Request 4

Please confirm or deny if Wye Valley NHS Trust holds information on the number of people diagnosed in Wye Valley NHS Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer in each year from 2013 to 2018.

If confirm, please release this data.

Request 5

Please confirm or deny if Wye Valley NHS Trust holds information on the numbers of people diagnosed in Wye Valley NHS Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer that were offered tumour profiling tests to guide adjuvant chemotherapy decisions in each year from 2013 to 2018.

If confirm, please release this data.

Request 6

Please confirm or deny if Wye Valley NHS Trust holds information on the number of people diagnosed in Wye Valley NHS Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer that were tested with tumour profiling tests to guide adjuvant chemotherapy decisions in each year from 2013 to 2018.

If you have queries or any concerns contact details are given at the top of the letter. Please remember to quote the reference number above in any future communications.

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to:

Information Governance/Privacy Officer
Wye Valley NHS Trust
Monkmoor Court

Glen Burley, Chief Executive

Russell Hardy, Chairman

31-34 Commercial Road
Hereford
HR1 2DX
Email: freedom.information@wvt.nhs.uk

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at:

Information Commissioner's Office
Wycliffe House,
Water Lane,
Wilmslow,
Cheshire, SK9 5AF

Telephone: 01625 545 745 www.ico.gov.uk

Yours sincerely,

Freedom of Information Coordinator

Re-Use of Public Sector Information

All information supplied by the Trust in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2005, Statutory Instrument 2005 No. 1515 which came into effect on 1st July 2005.

Under the terms of the Regulations, the Trust will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however the Trust reserves the right, in certain circumstances, to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information can be found at www.opsi.gov.uk where a sample license terms and fees can be found with guidance on copyright and publishing notes and a Guide to Best Practice and regulated advice and case studies, at www.opsi.gov.uk/advice/psi-regulations/index.htm